Lenvatinib
- Generic Name
- Lenvatinib
- Brand Names
- Lenvima 10, Kisplyx, Lenvima
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19ClN4O4
- CAS Number
- 417716-92-8
- Unique Ingredient Identifier
- EE083865G2
- Background
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular ...
- Indication
Lenvatinib is indicated for the treatment of the following cancerous conditions:
Differentiated Thyroid Cancer (DTC)
Renal Cell Carcinoma (RCC)
Hepatocellular Carcinoma (HCC)
Endometrial Carcinoma
- Associated Conditions
- Advanced Renal Cell Carcinoma, Endometrial Carcinoma, Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally advanced radioactive iodine-refractory Differentiated Thyroid Cancer (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Cancer (DTC)
- Associated Therapies
- -
Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 32
- Registration Number
- NCT06114940
- Locations
- 🇨🇳
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing, Jiangsu, China
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT06110793
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
- Conditions
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 104
- Registration Number
- NCT06089382
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT06070636
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-10-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Registration Number
- NCT06068153
- Locations
- 🇪🇸
Hospital Universitario Y Politécnico La Fe, Valencia, Spain
🇦🇹Medical University of Innsbruck / UK für Innere Medizin V, Innsbruck, Austria
🇨🇭Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 40
- Registration Number
- NCT06061276
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guanzhou, Guangdong, China
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06036836
- Locations
- 🇨🇳
Taichung Veterans General Hospital-GYNECOLOGY ( Site 0033), Taichung, Taiwan
🇨🇳National Cheng Kung University Hospital-Clinical Trial Center ( Site 0032), Tainan, Taiwan
🇨🇳National Taiwan University Hospital ( Site 0031), Taipei, Taiwan
Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT06032845
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Diwakar Davar
- Target Recruit Count
- 56
- Registration Number
- NCT06030037
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06028633
- Locations
- 🇨🇳
Peking University First Hospital Ethics Committee, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.